Genetic and epigenetic alterations in melanoma by Tuominen, Rainer
 From DEPARTMENT OF ONCOLOGY AND PATHOLOGY 
Karolinska Institutet, Stockholm, Sweden 
GENETIC AND EPIGENETIC 
ALTERATIONS IN MELANOMA 
Rainer Tuominen 
 
 
 
 
 
Stockholm 2015 
 
  
 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
© Rainer Tuominen, 2015 
ISBN 978-91-7549-905-5 
Printed by Universitetsservice US-AB, Stockholm. 
 Department of Oncology-Pathology 
Karolinska Institutet, Stockholm, Sweden 
 
 
GENETIC AND EPIGENETIC  
ALTERATIONS IN MELANOMA 
 
by Rainer Tuominen 
 
 
Thesis for PhD degree to be defended on Friday the 24th of April 2015 
at 13.00 Siewertsalen Z5:00 
  
Principal Supervisor: 
Professor, MD Johan Hansson 
Karolinska Institutet 
Department of Oncology and Pathology and  
Division of Oncology 
 
Co-supervisor: 
PhD Suzanne Egyházi Brage 
Karolinska Institutet 
Department of Oncology and Pathology 
 
 
 
 
Opponent: 
Associate professor Per Guldberg 
Danish Cancer Society Research Center 
Copenhagen, Denmark 
 
Examination Board: 
Professor Nico Dantuma 
Karolinska Institutet, Stockholm, Sweden 
Department of Cell and Molecular Biology 
 
Associate professor, MD Oddbjørn Straume 
Bergen University and Haukeland University 
Hospital, Bergen,Norway 
Department of Clinical Science 
 
 
Associate professor, MD Svetlana Bajalica 
Lagerkrantz 
Karolinska Institutet and Karolinska University 
Hospital, Stockholm, Sweden 
Department of Oncology and Pathology 
and Division of Oncology 
 
 
 
 
 
 
Stockholm 2015
 All that’s in a name is a puff of sound, a lungful of wind, and yet it is an airy 
enclosure. How is it that the gist, the spirit, the complicated web of bone, hair, 
brain, gets stuffed into a syllable or two? How do you shrink the genie of human 
complexity? How the personality? Unless, that is, your mother gives you her 
name, Other Side of the Earth.  
 
By Louise Erdrich in the Antelope Wife 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is dedicated to my wife Pia and my children Felix and Mira without 
whom I wouldn’t have insisted on continuing to decipher the endless unknowns 
of the clinical data... 
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ABSTRACT 
Malignant melanoma is a disease that may arise in several different parts of the body, 
preferentially the skin, rarely in the mucosal membranes or the choroidal tissues of the eye. 
The incidence of cutaneous melanoma (CMM) is steadily increasing in the Caucasian 
populations, unlike uveal melanoma (UM) that shows a stable incidence. The increase is 
likely to be related to t UV-irradiation leading to genetic aberrations that allow skin 
melanocytes to develop unlimited growth and immortality and ultimately lead to metastases.  
Paper I presents a genomic and epigenomic screening of 77 metastatic cutaneous melanoma 
metastases for the protein expression of p16
INK4A
 in relation to 3 well-known causes of 
expression loss: truncating and non-synonymous mutations in CDKN2A, the gene for 
p16INK4A, transcriptional silencing of p16
INK4A
 gene promoter and previously studied 
deletions in the CDKN2A loci encompassing p16
INK4A
. These aberrations were compared to 
p16
INK4A
 expression in tumours and presence of mutations in BRAF and NRAS genes. 
Unexpectedly, a significant association between tumours carrying NRAS mutations and 
transcriptional silencing of p16
INK4A
 promoter was observed. 
Paper II was a case study of a family with multiple cases of uveal melanoma. Family 
members with were found to be negative for germ-line CDKN2A aberrations, why next 
generation sequencing was employed. The proband, the proband’s sister and both parents 
were analyzed. The final mapped and filtered variants were filtered against variants found in 
the DNA of the non-carrier mother. A germ-line, frame-shift, insertion in BAP1 (exon 3 
c.75insG) was identified and validated by Sanger sequencing. The insertion leads to a 
truncation at codon 43 and was found to segregate with the disease.  
Paper III is a retrospective study to evaluate the naturally occurring transcriptional silencing 
of DNA repair protein O
6
-methylguanine DNA methyltransferase, MGMT. MGMT activity 
counteracts the efficacy of alkylating chemotherapy. Two cohorts of patients mainly derived 
from Sweden (n=74) and Belgium (n=79) were included, in total encompassing 191 tumours. 
The hypermethylation of MGMT gene promoter was found in 21.5% of tumours successfully 
analyzed (28 positive, 130 total) and to be associated with a significantly longer progression 
free survival (PFS) and to be an independent variable in a multivariate analysis for PFS. 
Paper IV is an in vitro melanoma study for combination therapy efficacy. The BRAFV600E- 
melanoma cell line A375 and a mutant BRAF inhibitor (BRAFi)-resistant subline were 
subjected to sequential and simultaneous exposures for BRAFi PLX4720 and temozolomide 
(TMZ). Administration order was found to influence the treatment outcome: administration 
of BRAFi followed by TMZ displayed a poorer efficacy compared to exposure 
simultaneously or administration in the reverse order. This effect was related to BRAFi 
induction of MGMT mRNA and protein, but also induction of the DNA damage marker 
H2AX by BRAFi and TMZ. 
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LIST OF ABBREVIATIONS 
ATP Adenosine triphosphate 
BAD Bcl-2 associated death promoter 
BAD BCL2-associated agonist of cell death 
BAP1 Bap1, BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase)  
BARD1 BRCA1 associated RING domain 1 
BCL2 B-cell CLL/lymphoma 2 
BRAF Braf, B-Raf proto-oncogene, serine/threonine kinase  
BRCA1 Breast cancer 1, early onset 
CDK4/6 Cdk4, cyclin dependent kinase 4/ Cdk4, cyclin dependent kinase 6 
CDKN2A p16INK4A , Inhibitor of CDK4/CDK6 and p14ARF ,Alternative Reading Frame  
CMM Cutaneous malignant melanoma (skin melanoma excluding melanoma in mucosal  
membranes but including acral melanoma) 
CpG Cytosine-phosphate-guanine 
CREB1 cAMP responsive element binding protein 1 
E2F1 E2F transcription factor 1 
EGFR/ERBB1 Epidermal growth factor receptor 
ELK1 ELK1, member of ETS oncogene family 
ERBB2/Her2 Erb-b2 receptor tyrosine kinase 2 
ERBB3/4 Erb-b2 receptor tyrosine kinase 3f/ erb-b2 receptor tyrosine kinase 4 
ERK1/2,MAPK3/1 Mitogen-activated protein kinase 3/ mitogen-activated protein kinase 1 
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EZH2 Enhancer of zeste 2 polycomb repressive complex 2 subunit 
FOS FBJ murine osteosarcoma viral oncogene homolog 
GAB1/2 GRB2-associated binding protein 1/2  
GDP Guanosine bis-phosphate 
GNA11 Guanine nucleotide binding protein (G protein), alpha 11 
GNAQ Guanine nucleotide binding protein (G protein), q polypeptide 
GPCR G-protein coupled receptor 
GRB2 Growth factor receptor-bound protein 2 
GRM3 Glutamate receptor, metabotropic 3 
GSK3β/GSK3B Glycogen synthase kinase 3 beta 
GTP Guanosine tris-phosphate 
IGF1R Insulin-like growth factor 1 receptor 
JUN Jun proto-oncogene 
KIT/CD117 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
MEK1/MAP2K1 Mitogen-activated protein kinase kinase 1 
MEK2/MAP2K2 Mitogen-activated protein kinase kinase 2 
MGMT Mgmt, O-6-methylguanine-DNA methyltransferase 
MITF Mitf-M, Microphthalmia-associated transcription factor 
MTOR mTOR, mechanistic target of rapamycin (serine/threonine kinase) 
mTOR/MTOR Mechanistic target of rapamycin (serine/threonine kinase) 
NGFR/CD271 CD271, Nerve growth factor receptor 
Non-RTK Non-receptor tyrosine kinase 
NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog 
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PIK3CA/PIK3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIP3 Phosphoinositol-1,4,5-trisphosphate 
PIP3 Phosphatidylinositol-4,5-bisphosphate 
PLCγ/PLCG1 Phospholipase C, gamma 1 
RTK Receptor tyrosine kinase 
SETDB1 SET domain, bifurcated 1 
SHC/SHC1 SHC (Src homology 2 domain containing) transforming protein 1 
SOS Son of sevenless homolog 1 (Drosophila) 
SRC SRC proto-oncogene, non-receptor tyrosine kinase 
STAT3/5A/B Signal transducer and activator of transcription 3/ signal transducer and  
activator of transcription 5A and 5B 
TP53 P53, tumor protein p53 
UM Uveal melanoma including anterior and posterior uveal melanoma, but excluding  
melanoma in the accessory parts of the eye (the wider term being ocular melanoma) 
ZEB1/2 Zeb1, Zinc finger E-box binding homeobox 1 /2 
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1 MELANOMA ETIOLOGY AND CHARACTERISTICS 
 
1.1 Cutaneous melanoma incidence, trends and mortality 
Cutaneous malignant melanoma (CMM) is a cancer disease that displays a growth of 
incidence in most populations of Caucasian origin, including Sweden. Among 61297 
registered cancer tumours in Sweden year 2013, 3027 tumours (from 2831 patients) i.e. 4.9 % 
were diagnosed as cutaneous malignant melanoma. This made cutaneous malignant the 6
th
 
most common cancer disease among men and the 5
th
 most common cancer diagnosis among 
women (National Board of Health and Welfare, 2013).  
The age-standardized incidence of CMM in Sweden 2013 was 35.6 for males and 32.1 for 
females per 100 000 inhabitants (age-standardized according to the Swedish population).  
These, relatively equal, incidences have nearly doubled in Sweden since year 2000, the 
present yearly increase in incidence being 5.5 % for men and 5.2 % for women (National 
Board of Health and Welfare, 2013). 
The cumulative risk for development of CMM before the age of 75 years of age 2013 was 
2.1%, same for both sexes, but also 0.2 % before the age of 35 years for women (0.1% for 
men), i.e. at the same level as the risk of developing breast cancer for this age group (National 
Board of Health and Welfare, 2013).  
As shown in Figure 1, the incidence of CMM in Nordic countries years 2000-2012 shows a 
near linear increase, but this increase is not followed by increase in mortality, indicating 
diagnostic and therapeutic progress.  Despite the higher incidence for CMM for women in the 
Nordic countries, CMM mortality for females is lower than that of males (Figure 1). Reasons 
for the better survival for females may include lower median age at diagnosis, lower median 
Breslow thickness of primary tumors and earlier detection, but female gender is a positive, 
independent variable for survival even when tumor stage is accounted for (1), (2). This 
gender difference on overall survival has been related to differences between sexes regarding 
tumor localization and pathologic variables:  proliferative index, histological subtype and 
tumor vascularization and ulceration in a study with relatively few patients (nfemales=132, 
nmales=123 (3). The gender difference is also evident in a larger proportion of males 
experiencing emergency presentation, i.e. disease is diagnosed together with need of 
immense actions by the health care as analyzed using hospital records from 27 different 
countries. This difference was suggested to be related to lower level of body consciousness 
and ability to seek help for males compared to females (4).  
The long-term trend in cutaneous melanoma with improved therapy outcome is evident as 
surviving fractions by 4-year intervals between 1964 and 2012 in the Nordic countries, but 
also shows a larger improvement among males compared to females (Figure 2) (NORDCAN 
). The mortality trends for both CMM and UM can be collectively described as cautiously 
optimistic, mortality possibly reaching a plateau. 
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Figure 1. Incidence and mortality trends for cutaneous malignant melanoma in the Nordic 
countries 2000-2012. Mortality data is not available for all countries for 2010-2012. 
Incidence and mortality as age standardized rates/100 000 inhabitants (NORDCAN ). 
 
Figure 2. Long-term improvement in surviving fraction (median for all Nordic countries) for 
CMM 1964-2012. Adapted from NORDCAN database numerical data. 
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1.2  Cutaneous melanoma association with phenotype, UVR and SES 
Factors found to be associated with an increased risk for developing cutaneous malignant 
melanoma are Caucasian ancestry and phenotypic traits like poor tanning response (skin 
types I and II), red hair color, skin with appearance of freckles, dysplastic nevi or excessive 
number of normal nevi and documented familial history of CMM (5). In general, cumulative 
UV irradiation is not regarded to be related to CMM risk unlike the other skin diseases like 
squamous cell carcinoma and basal cell carcinoma. Whether an intermittent UV irradiation 
causing sunburns, possibly in particular during childhood, increases risk for CMM is debated 
and, due to the retrospective nature and length of the retrospective period, highly challenging 
to study (6). Still, the apparent increased CMM risk for individuals migrating from higher to 
lower latitude countries compared to non-migrating subjects and the higher CMM incidence 
found to be associated with higher socio-economic status (SES), suggestive of more 
recreational UV exposure, strongly implies intermittent UV irradiation to be involved in 
CMM etiology (7), (8). Possibly, vitamin D influx via sun exposure and diet and UVR-
initiated formation of ROS in melanocytes are confounding factors here (9), (10). 
Behind the phenotypic traits are differences associated with impaired function of the 
eumelanin production, the common phenotypic variation (without outright albinism) being 
most prominent for melanocortin-1 receptor (MC1R) protein by non-synonymous amino acid 
changes. MC1R is regarded as a low to median penetrance CMM susceptibility gene. 
Carriage of 2 or more variants for MC1R was found to increase the risk for CMM with an 
OR 2.51 (95% CI: 1.83–3.44) (OR corrected for study-specific factors). All variants 
associated with appearance of red or blond hair color were significantly associated with 
increase in CMM risk. In addition, carriage of MC1R variants without the typical red 
hair/blond hair and fair skin color was shown to be associated with increase in CMM risk. 
This implies that MC1R function may have CMM related effects beyond those related to the 
phenotype (11).  
Heredity for CMM includes shared genetic variants associated with the phenotype, but also in 
~5-10% of all families with increased number of CMM cases, germ-line aberrations are 
found. Around the world, these mutations are dominated by regionally distinct variants in 
CDKN2A. Also, rare germ-line mutations in CDK4 are found as well as aberrations in genes 
MITF, TERF2IP, ACD, POT1 and BAP1 albeit all at a low frequency (12). As the prevalence 
of heredity in CMM is low, the contribution of germ-line mutations for CMM pathology is 
limited, but several of the germ-line altered genes are found to be somatically altered as well. 
In addition, as some of these genes increase the risk for development of other neoplasms 
(pancreatic cancer for CDKN2A and CDK4; UM for BAP1), screening of the alterations is 
useful for identification of subject on heightened risk for cancer.  
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1.3  Uveal melanoma etiology and association to phenotype 
The incidence of uveal melanoma (UM) is considerably lower that of CMM, a total of 114 
cancer cases in the eye were registered in Sweden during 2013, including retinoblastoma, 
uveal melanoma and some rare neoplasms, but excluding tumors in the accessory organs of 
the eye, like the eyelids.  In adults, a majority of eye neoplasms are uveal melanoma with 
posterior localization being most common, anterior neoplasms in the ciliary body or iris are 
rare, but have a better prognosis compared to the posterior tumors (13). A difficulty in 
diagnosis of UMs is distinguishing UM from benign uveal nevi, necessitating watchful 
waiting to avoid unnecessary therapeutic intervention.  
The UM risk factors are fairly similar to the risk factors for CMM, increased risk is 
confirmed to be associated with light eye color (blue or grey, i.e. absence of eumelanin in the 
iris), Caucasian ancestry, light skin complexion and sun sensitive skin. A difference may 
however be that red/blond hair color appears not to be associated with higher risk of UM 
(13). Also, presence of dysplastic dermal nevi or freckles, presence of iris nevi or numerous 
normal dermal nevi increase the risk of UM development (13). For UV exposure, no obvious 
effect of latitude or occupational/ recreational UV exposure on UM risk was found, with the 
exception of welding as an occupation (14). An obvious difficulty in studying risk factors for 
UM is the relative rarity of the disease, why virtually all studies are either low in power or 
ethnically limited, consequently well-controlled meta-analyses are better suited for the risk 
estimates offering enhanced statistical power.  Overall, the recognized risk factors for CMM 
and UM are overlapping to a high degree. 
Hereditary accumulation of UM has been shown to be associated with germ-line aberrations 
in BAP1, in particular truncating BAP1 mutations, leading to an increased risk for UM, 
CMM, mesothelioma, clear cell renal cancer and paraganglioma. Other rare cancer diseases 
have also been suggested to be associated with BAP1 germ-line alterations in single family 
contexts.  Whether specific alterations in BAP1 are differentially associated with the tumor 
types is not well understood, but this appears unlikely for UM and CMM, the two most 
commonly seen tumor types. As apparent, this wide spectrum of cancer diseases associated 
with BAP1 requires a multi-disciplinary approach to identify and manage the family 
members who are carriers of these germ-line variants (15). 
 
1.4 Genetic aberrations and melanoma associated pathways 
 
Genetic aberrations associated with neoplastic development in CMM and UM have long been 
regarded to be rather different, mainly due to obvious lack of evidence for inactivation of 
CDKN2A and nearly absent presence of oncogenic mutations in BRAF and NRAS in UM. 
Lately, however, some common genetic aberrations have been confirmed to exist, forming a 
more coherent picture of these diseases, both associated to Caucasian origin and fair 
complexion. This common phenotypic context makes it likely that phenotype-related gene 
variants are common in both patient groups and that the effect of phenotype is related to 
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mutational patterns typical of UV induced mutations in UM similar to CMM.  Evidence for 
this is, however, only available for CMM presently. 
 
The early expansion of tumor cells in CMM and UM is illustrated in cartoons (Figures 3 and 
4).  
 
 
 
Figure 3. Schematic illustration of early CMM spread though the basal cell membrane to the 
dermal space. A. Normal dermis-epidermis boundary B. Spread of melanoma cells to the 
dermis. The cells and dermal layers are not proportionally illustrated. 
 
  
 
Figure 4. Schematic illustration of posterior uveal melanoma initiation and growth towards 
the retina.   
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1.4.1 Major pathways activated in melanoma 
 
The major pathways activated in CMM tumors are MAPK pathway (RAS-RAF-MEK-ERK) 
and PI3K pathway (PIK3CA-AKT-mTOR). Both pathways are known to be directly 
activated by oncogenic signaling by some RTKs (EGFR, MET, KIT), whereas any of the two 
pathways are activated by many RTKs (VEGFR, IGF1R, EPHA2, FGFR).  In addition, 
MAPK pathway is activated by oncogenic mutations in RAS (in CMM dominantly NRAS) or 
BRAF leading to a constitutively active MAPK downstream signaling and unregulated 
expression of Cyclin D1 protein as one of the high impact oncogenic events (Figure 5)(16) . 
 
Some G-protein coupled receptors (GPCRs) have been shown to carry mutations in the 
intercellular C-terminal part rendering them to signal constitutively downstream activating 
MAPK pathway. GRM3 mutations are best studied leading to increased ERK 
phosphorylation, although the exact downstream signaling details are not known (Figure 
5)(17) In addition, phenotype-related GPCR MC1R with downstream signaling via the cyclic 
AMP mediated pathway may be involved in oncogenic signaling in CMM. 
 
Similarly, in UM, constitutive MAPK pathway activation has been shown to take place, but 
the identified alterations associated with this activation are overexpression of RTKs (KIT, 
IGF1R and MET) and constitutive signaling from GPCRs GNAQ and GNA11 leading to 
activation of MAPK, but also signaling to PLCγ in the PI3K-AKT pathway (18). 
 
Figure 5. Cartoon depicting some major oncogenic pathways in CMM and their upstream 
activation. Data compiled using (19), (20),(21),(22),(23),(24) 
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1.4.2   Oncogenic alterations in CMM 
In malignant melanoma, a number of mechanisms leading to neoplasia have been described. 
Cutaneous malignant melanoma development has been known since 1994 to be associated 
with sporadic loss of p16
INK4A
 protein translated from one of two reading frames of the gene 
CDKN2A . Similarly, association between germ-line mutations in CDKN2A and aggregation 
of CMM in families has been recognized (25). CDKN2A has two reading frames giving 
P16
INK4A
 protein which is a repressor of cyclin dependent kinases CDK4 and CDK6, 
preventing their association with type D cyclins, and most prominently cyclin D1. This 
results in negative regulation of the retinoblastoma protein due to hypophosporylation 
preventing Rb-E2F1 association and E2F1 function as a transcription factor. Loss of this 
tumor suppressive mechanism leads to attenuated G1-S cell cycle blockage and inability to 
induce cellular senescence. The second reading frame gives p14
ARF
 protein which inhibits 
MDM2. Loss of this tumor suppressive protein inhibits the p53-dependent functions in 
apoptosis and prevents G2/M cell cycle checkpoint engagement (26). 
CMM are loss of the tumor suppressor gene, CDKN2A derived proteins and constitutive, 
oncogenic activation of the RAS-RAF-MEK-ERK (MAPK) pathway by oncogenic 
mutations, primarily in genes for BRAF and NRAS. When accounting only alterations 
(mutations and copy number changes) in any of these three genes, 67% of CMM possess 
such alterations with 32% in CDKN2A, 39% in BRAF and 21% in NRAS. These alterations 
are convincingly related to melanoma development as BRAF and NRAS alterations are 
significantly mutually excluding both being within the MAPK pathway, and that virtually all 
alterations are deactivating for CDKN2A (deletions and mutations),  but activating for BRAF 
and NRAS (mutations and amplifications)(28)(TCGA database). In addition, CDKN2A is 
deactivated transcriptionally by promoter methylation in ~20 % of melanoma metastases 
(27). 
Among relatively common alterations not accounted above are the enhanced mRNA 
expression or, rarely, mutation of GLI family zinc finger 1/2/3 (GLI1/GLI2/GLI3) in 8%, 
11% and 16% of CMM.  The two former are positive transcription factors of the sonic 
hedgehog (SHH) pathway, whereas GLI3 is regarded a negative regulator for the same 
pathway. The pattern for the aberrations does not support a simple association to CMM, in 
particular as the protein expression of both GLI1 and GLI3 appears to be elevated in CMM 
tumors (28)(TCGA database), (29)(Human Protein Atlas). In addition and  important for 
CMM tumors without BRAF or NRAS mutations, cyclin D1, the commonly deregulated 
cyclin in many cancers including melanoma and a downstream target for transcriptional 
activation by MAPK pathway and a RB1-E2F1 transcriptional target, is increased by mRNA 
up-regulation in 10% and by gene amplification in 5 % of CMM tumors. The gene 
amplifications are mainly found in acral or lentiginous subtypes which are associated with 
chronic sun exposure. A similar downstream  example of aberrant signaling in melanoma is 
the increased mRNA expression and gene amplification of the  transcription factor v-myc 
avian myelocytomatosis viral oncogene homolog (MYC), present in 9 % of CMM (with 
additional, rare mutations)  (28) (TCGA database). These two last aberrations are likely to 
represent downstream signaling activation and may have effects equal to upstream activating 
oncogenic events for these tumors.    
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1.4.3   RTK activation in CMM 
In addition to these genetic features CMM tumors display a prominent activation of multiple 
receptor tyrosine kinases (RTKs), primarily by enhanced mRNA and protein expression 
rather than by mutation or gene amplification. The RTKs found to be commonly deregulated 
account for 14% alterations in CMM for the hepatocyte growth factor receptor MET proto-
oncogene (MET), 13% for the insulin-like growth factor 1 receptor (IGF1R), 13 % KDR 
(VEGFR and VEGFR2), 12% for KIT, 11%  EGFR, 11 % PDGFRA and 10% in EPHA2. 
The increased mRNA expression of RTKs may possibly be partially a result of downstream 
RTK signaling activating the melanocyte lineage specific transcription factor MITF via beta-
catenin (CTNNB1) or via the leucine zipper transcription factor cAMP responsive element 
binding protein 1 (CREB1) downstream of MAPK pathway. CREB1 may also respond to 
cAMP signaling downstream of MC1R. Enhanced mRNA and protein expression in 
melanoma tumors is also indicated for MET, IGF1R, AXL, ERBB3, PDGFRα and EPHA2 
(29)(Human Protein Atlas),(20). Autocrine signaling has been described for RTKs AXL, 
PDGFRβ and FGFR3 (30), (20). KIT RTK, which is highly expressed in normal 
melanocytes, may have both oncogenic and tumor suppressive roles in CMM as it is found to 
be mutated and or amplified in 11% of CMM tumors (TCGA), but has also been reported to 
be transcriptionally inactivated by promoter methylation in ~30% of CMM metastases (31). 
These RTK alterations are accompanied by loss of PTEN in 16% of CMM leading to loss of 
negative regulation of PI3K-AKT pathway and its downstream effector mTOR. Also, in 17% 
of CMM, alterations in neurofibromin 1 (NF1) are found, allowing an enhanced RAS 
activation due to loss of NF1 induction of GTPases (i.e. loss of GTP depletion for RAS 
proteins).  NF1 is often co-altered with NRAS mutation in CMM, but also, transcriptionally, 
both decreased and increased indicating diverse signalling. PTEN loss is primarily due to 
gene deletion or transcriptional silencing and shows a significant co-occurrence with BRAF 
mutation (28) (TCGA database). In addition mutations, and to a lesser degree mRNA up-
regulation, of GRIN2A and GRIN2B, two ion-gates for mono- and divalent cations and 
glutamate receptors, are commonly found in CMM (19% and 15%, respectively)(28) (TCGA 
database). These receptors are important in mammalian neuronal cells as excitatory 
neurotransmitter receptors, but may have functions of similar importance in melanocytes and 
melanoma cells belonging to the neuro-endocrine lineage of cells.  
1.4.4 Downstream signaling from RTKs in CMM 
The classic RTKs found to signal downstream in unregulated way are HGF receptor cMET 
and EGF receptor EGFR. Both receptors have intercellular domains capable of signaling via 
GRB2 and GAB1 to activate both MAPK and PI3K-AKT pathways (Figure 5).  The 
signaling may be constitutively active as a result of RTK mutation leading to persistent 
tyrosine kinase activity by the RTK kinase domain or by mutational inactivation of RAS 
locking the RAS protein in a constitutively active, GTP-bound state. This constitutive 
activation leads to a deregulated signaling via MAPK and PI3K-AKT pathways resulting in 
increased proliferation, inhibition of apoptosis, loss of contact inhibition, altered cellular 
metabolism, increased migration and enhanced metastatic capacity of melanoma cells. 
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Among the most important downstream targets of MAPK are the AP-1 transcription complex 
(Jun/Fos) and transcription factors CREB1, ELK1 and STAT3. The most prominent 
downstream effector for the PI3K-AKT pathway is regarded to be mTOR (Figure 5).  
ERBB-family RTKs like EGFR, ERBB2 and ERBB3 may have a different signaling via 
formation of heterodimers between EGFR or ERBB2 and ERBB3, followed by trans-
phosphorylation of the auto-phosphorylation-negative ERBB3 kinase domain (Figure 5). 
These heterodimers are not inhibited by common small molecule inhibitors of EGFR or 
targeted antibodies for ERBB2 resulting in a constitutive activation of the PI3K-AKT 
pathway.   
The non-RTK dependent effects include overexpression or aberrant phosphorylation of Src 
family kinases leading to downstream activation of STAT3 and STAT5, two transcription 
factors with pro-survival effects via inactivation of apoptosis (23) JAK activation of STATs 
may take place in a subgroup of melanomas, but mutations in JAK1 and JAK2 are rare (28) 
(TCGA database). 
1.4.5. Genetic aberrations in uveal melanoma 
Unlike CMM, in uveal no BRAF or NRAS mutations are demonstrated in UM tumors (32). 
Instead, oncogenic mutations in two G-protein coupled receptors, guanine nucleotide binding 
protein (G protein), q polypeptide (GNAQ) and guanine nucleotide binding protein (G 
protein), alpha 11 (Gαq class) (GNA11), two α-type G proteins that are frequently found to be 
mutated in UM in glutamine 209 (33% and 39% of UM, respectively) rendering the proteins 
constitutively active in the GTP-bound state (Figure 6). CMM carries GNAQ and GNA11 
mutations also, but at a much lower frequency ~1.5% of CMM. Few inactivated tumor 
suppressor proteins have been demonstrated in UM, BAP1 being the sole commonly found 
tumor suppressor gene found to be altered (18) but recently epigenetic inactivation of 
p16
INK4A
 has been reported in UM (33) indicating a role for p16
INK4A
 in UM development. 
The metastatic potential of UM has been reported to be associated with a decrease in ERBB3 
mRNA and an increase in KIT mRNA (34)  
On the other hand, loss of heterozygosity in 3p arm (including locus for BAP1) and 
amplification of 8q are associated with increased propensity of the UM to metastasize and 
therefore a worse prognosis (34). 
Aberrant RTK protein expression has also been associated with UM tumors for RTKs KIT, 
IGF1R and MET, although no frequent mutations in these RTKs have been demonstrated 
(Figure 6)(35), (36), 
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Figure 6. Cartoon for known activated oncogenic pathways in UM. The data was compiled 
from (18), (35), (36).
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1.5 Melanoma epigenetics  
In addition to gene deletion and mutational alteration of protein activity, epigenetic 
alterations in DNA and histones have recently become a part of melanoma genetic 
aberrations. Epigenetic alterations are regarded to be related to transcriptional deregulation 
leading to loss of tumor suppressor gene expression (transcriptional silencing) and/or up-
regulation of genes for proteins with enhanced expression in malignant cells compared to 
normal cells (37) Also, epigenetic alterations of transcription with effect on transcription 
factor binding to DNA have obvious potential to lead to cellular adaptation towards increased 
survival (38). 
1.5.1 Transcriptional silencing and histone modifications 
Epigenetic regulation of gene expression has been associated with silencing of tumor 
suppressor genes in melanoma, more prominently genes like CDKN2A, RASSF1A and PTEN 
(39),(40), (41),(42). The transcriptional silencing by aberrant promoter methylation is 
associated with di-methylated lysine 9 in histone 3 (me2H3K9), resulting from activity of 
H3K9 histone methyltransferases like SETDB1 and EHMT2 and counteracted by H3K9 
histone demethylase LSD1 (43). The transcriptional repression is believed to require binding 
of methyl CpG binding protein 2 (MECP2) and methyl CpG domain binding protein 1 and 2 
(MBD1 and MBD2) activity. MBD1 is also a binding partner to SETDB1 (38).  
Another epigenetic complex that regulates gene transcription is the polycomb repressive 
complex 2 (PRC2) that interacts with DNA methyltransferases and is associated with tri-
methylated H3K27. EZH2 is the catalytic subunit of PRC2 with H3 methyltranferase activity. 
Ectopic overexpression of miR-124a, that regulates EZH2 negatively, has been shown to 
decrease tumor growth in vivo in CMM and to be related with tumor aggressivity. Similar 
effects have been observed by miR-124a in UM verifying that EZH2 down-regulation is 
important in melanoma (44, 45) (46).  
Other histone lysine modifications that are suggested to be related with epigenetic 
modification of transcription and accessibility of gene promoters are histone (lysine) 
acetyltransferases (HATs) like PCAF that is associated with p300 and CREB transcriptional 
activation and histone deacetyltransferases (HDACs) that remove acetyl groups from histone 
lysines (37).  
Similar to CMM transcriptional silencing by promoter methylation for p16
INK4A
 in UM has 
been reported in 50% of tumors analyzed, but only six respective 22 tumors were included in 
these screenings (33), (47).  
1.5.2 miRNA related regulation 
Additional epigenetic regulation of protein expression derives from miRNA that may have 
effects on gene expression or protein stability that affects the oncogenic process. One 
example of this is miR-125b having been shown to be a negative regulator of the MAPK 
 18 
 
downstream target c-Jun by altering translation or protein stability. Forced expression of 
miR-125b was found to suppress cellular proliferation and migration in line with MAPK 
pathway down-regulation (48). 
1.5.3 Alterations in epigenetic regulators  
Loss of gene regulation in melanoma may be association to epigenetic regulation may be a 
result of mutations in genes coding for epigenetic regulators of gene expression. Alterations 
in EZH2 or SETDB1 are found in 37% of all CMM tumors accounting increased mRNA 
transcription, gene amplification and mutation (28)(TCGA database). This high frequency 
together with appearance of EZH2 mutations in the catalytic domain suggest a role these and 
possibly other epigenetic regulators to be associated with the oncogenic potential of 
melanoma. 
 
1.6 Malignant melanoma therapy  
 
1.6.1 CMM therapy options and outcomes 
Although early detection and surgical removal of melanoma does, in ~90% of diagnosed 
cases offer cure for the disease, when surgery is not sufficient to remove the melanoma cells, 
risk for metastatic spread of the disease is high. For cutaneous melanoma primary tumor 
thickness (Breslow thickness) and melanoma propensity to metastasize to multiple tissues 
(lymphatic tissues, soft tissues, lung, CNS) (49) For uveal melanoma, the metastatic spread is 
often limited to the liver and may allow therapy using liver perfusion and high local dose of 
chemotherapy (50). 
The classic systemic therapy for disseminated cutaneous melanoma has been alkylating 
agents like DTIC (dacarbacine), TMZ (temozolomide) as monotherapies or together with 
platinum compounds (cisplatin or carboplatin), other alkylating drugs (fotemustine, 
melphalan) or immunostimulatory agents (interleukin-2 (IL-2), interferon (IFN)).  Neither the 
single agent therapies nor combinations of different types of agents have been particularly 
successful in therapy, displaying response rates (RR) of 5-12% and median overall survival 
(OS) <1 month to 8 months (51). However, a large phase III trial NCT00091572 for stage IV 
patients, 429 patients receiving TMZ (150mg/m
2
 orally 7 consecutive days every 14 days) 
and 430 patients receiving DTIC (1000mg/ m
2 
intravenously day 1+/- 3days every 3 weeks) 
did show median OS of 9.1 months and 9.4 months, respectively, with corresponding 
objective response rates of 10% and 14% for TMZ and DTIC (52)(www.clinicaltrials.gov).  
In a meta-analysis data, and allowing pooling of data for DTIC and TMZ clinical trial 
monotherapies, a median OS length of 7.9 months has been established for chemotherapeutic 
drugs (51). As few patients respond to therapy and the sustained therapeutic efficacy is poor, 
alternatives to classic chemotherapy have been to treat patients systemically with high, 
 19 
 
intermediate or low dose IFN in the adjuvant setting. Meta-analysis of these clinical trials 
(3593 treated patients vs 2539 control patients (observation)) showed an overall decreased 
risk of death with IFN administration (OR 0.88 [CI 0.79-0.99], p=0.03) displaying a 
significant, but rather weak enhancement of therapeutic efficacy (51). 
1.6.2.  Uveal melanoma therapy options and outcomes 
For uveal melanoma, surgical removal of the eye, enucleation, is often required. Overall 
about 50% of all uveal melanoma patients develop metastatic disease, nearly 90% of these 
metastases being hepatic (50). As ocular melanoma has, similar to cutaneous melanoma, high 
propensity to metastasize, systemic therapy used historically composed of combination of 
dacarbacine and cisplatin together or combined with other chemotherapeutic agents or 
immunostimulatory drugs IL-2 or IFN (53). Local therapies to avoid enucleation like 
brachytherapy (54), transpupillary thermotherapy (TTT), stereotactic radiotherapy showing 
73% (95% CI; 61-86%) progression free survival at 3 years after single dose stereotactic 
radiotherapy in 60 patients, but these therapy forms are often limited to use for eligible 
patients only (anterior involvement for brachytherapy and TTT, stereotactic radiotherapy 
for posterior tumors) and is associated with partial loss of eyesight due to damage to normal 
tissues(50, 55).    
  
MEKi selumetinib was compared to chemotherapy with TMZ or DTIC as a monotherapy in 
an open-label phase II trial with 101 patients. Therapy with selumetinib was shown to 
prolong median PFS (15.9 weeks 95% CI [8.4-21.1] compared to 7.0 weeks 95% CI [4.3-8.4] 
for TMZ/DTIC) and a non-significant increase for median OS (11.8 months 95% CI [9.8-
15.7 months] compared to 9.1 months 95% CI [6.1-11.1 months](56). In this trial, the 
randomization for the therapy groups resulted in the chemotherapy group to receive a higher 
proportion of patients with measured levels of elevated serum lactate dehydrogenase (59%  
vs 50%) possibly leading to a bias towards shorter than expected PFS and OS for patients in 
the chemotherapy group. Also, 37% receiving MEKi selumetinib had dose reductions 
compared to 2% for the chemotherapy group plausibly causing opposing bias in the study. 
Ipilimumab (anti-CTLA-4 Ab) was also tested in a phase I trial for 13 patients, but no 
objective responses were observed (57). 
Regarding therapy efficacy in UM, loss of BAP1 expression in UM has been suggested to be 
related to induction of de-differentiation leading to a neuro-endocrinal stem cell like 
phenotype in UM cells associated with a pronounced membranous β-catenin staining. De-
differentiation may have pronounced effect on the therapy efficacy as stemness is generally 
associated with low proliferative capacity but high survival capacity (58). 
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1.6.3  Targeted and immunotherapies in cutaneous melanoma 
The introduction of targeted therapies for therapy of cutaneous melanoma has led to 
improvements of patient care (59). A phase III study comparing use of inhibitor against 
codon 600 mutated BRAF (Vemurafenib/Zelboraf, NCT01006980) versus chemotherapy 
with DTIC) in 336 treatment naive patients showed significantly prolonged OS for patients 
treated with targeted therapy  with OS of 84% of patients at 6 months  ( 95% CI; 78-89 %) 
compared to 336 patients receiving DTIC 64% (95 % CI;56- 73%). This study allowed 
crossing-over why final PFS and OS measurements were not reached (60),(52, 
61)(www.clinicaltrials.gov).  
In line with this, addition of inhibitor of non-mutated MEK (trametinib) did increase the 
efficacy of another BRAFi,  dabrafenib, further compared to using dabrafenib alone 
(NCT0158464) combination median PFS 9.3  [CI 7.7-11.1] RR 67% vs. monotherapy median 
PFS 8.8 months [CI 5.9-10.8] with RR of 51%. This can be compared efficacy measures of 
monotherapy with DTIC with median PFS 2.3 [CI 2.2-2.4] ORR  14%  and monotherapy 
with TMZ median PFS 2.2 [CI 2.1-2.3] ORR 10%  (61)(www.clinicaltrials.gov) 
These improvements in cutaneous melanoma therapy have been highly necessary, but require 
sustained drug administration and do not appear to give stable remissions. Median OS for 
BRAFi dabrafenib treated patients was 18.2 months [CI 16.6-not reached] at update of the 
study at Dec 2012 (Journal of Clinical Oncology, 2013 ASCO Annual Meeting Abstracts. 
Vol 31, No 15_suppl (May 20 Supplement), 2013: 9013), showing that half of the patients in 
dabrafenib monotherapy had succumbed at 1.5 years after therapy start.  
Cutaneous melanoma is considered to be responsive to immune therapies due to observations 
of rare, spontaneous regressions of primary tumours and more common appearance of tumor-
infiltrating lymphocytes (TILs) in melanoma tumours (62) immunotherapy against 
disseminated cutaneous melanoma has been developed in parallel with targeted therapy.  
The first immunotherapeutic to show potency for therapy was the cytotoxic T lymphocyte-
associated antigen-4 blocking antibody (anti-CTLA-4 antibody). CTLA-4 is a receptor found 
on TILs and regulatory T cells and does have higher affinity with the T cell co-activating 
receptor B7 (necessary for antigen-presenting derived immune response) than its endogenous 
ligand CD28. The latter is clearly a disadvantage in tumour cell vaccination with tumour cell 
derived antigens. A prolonged inactivating signaling for TILs leads to anergy of the cells. 
Blockage of CTLA-4 with the CTLA-4 specific antibody ipilimumab/Yervoy has led to a 
slow-onset therapeutic effect and short PFS but, in a minority of patients, a long-lasting 
remission.  This was originally shown in a phase II, three-arm, clinical trial involving 676 
stage III and IV patients comparing glycoprotein 100 alone, ipilimumab/Yervoy alone or a 
combination. Inclusion of ipilimumab/Yervoy was statistically beneficial for the patients, 
with ipilimumab/Yervoy alone (137 patients) showing a median PFS of 2.86 months (95% CI 
2.76 to 3.02), but a median OS of 10.1 months (95% CI 8.0 to 13.8). In this clinical trial, 7 (of 
total 14) deaths were due to severe immune response related adverse events (NCT00094653, 
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(63). Given the rather serious side effects of ipilimumab/Yervoy, in particular for GI tract, 
response markers for use of this drug would be very helpful. 
A clinical phase I, two-arm trial, NCT01295827 (64), with the anti-programmed-death-
receptor-1 (anti-PD-1) antibody pembrolizumab in 173 patients with ipilimumab-refractory 
advanced melanoma showed a ORR at 26% at both doses used (2mg/kg or 10mg/kg). Only 
3% of patients experienced grade 3-4 adverse effects   
As a part of another clinical dose-escalation study for anti-PD1 antibody, nivolumab, 107 
systemically pre-treated melanoma patients were studied (mixed cutaneous and uveal 
melanoma patients, NCT00730639) (65). Median PFS was 3.7 months, but at 2 years 27% of 
patients had not progressed. 2-year OS was 43 % and the median OS was 16.8 months 
showing a reasonably rapid onset of therapeutic efficacy and improved OS compared to 
chemotherapy. This clinical trial is difficult to evaluate due to multi-dosing and mixed patient 
inclusion, but shows that previously treated patients are not refractory to this therapy. 
Collectively, the clinical trials in cutaneous melanoma show a successive improvement in 
PFS and OS for melanoma patients with introduction of targeted and immunotherapies, but 
also a shift in therapy resistance from intrinsic to acquired resistance. The acquired resistance 
to targeted therapy is a very large field for research in CMM today, but the clinically most 
relevant question is likely not why resistance appears but how to avoid it from appearing in 
the first place. 
1.6.4  Targeted and immunotherapies in uveal melanoma 
A retrospective study has indicated therapies with ipilimumab, MEKi or anti-VEGF Ab 
bevacizumab to provide an inferior therapeutic outcome compared to local therapies (66). 
1.6.5 Future perspectives for melanoma therapy 
In general, the high mutational rate observed in (cutaneous) malignant melanoma cells is a 
potential source of therapy resistance. It increases the likelihood for the melanoma cells to 
become heterogenic as clones of melanoma cells develop aberrations in same pathways but in 
different components of the pathways (28)(TCGA database) (67)(the COSMIC database).  
The heterogeneity inducers other than diversity in genetic aberrations may include hypoxia, 
tumor microenvironment, selection by therapeutic agents and may be executed by reversible 
alterations of epigenetic changes in miRNA profiles or histone modifications and be seen as 
adaptations.   Malignant cutaneous melanoma exhibits showing relatively small number of 
tumors activated by mutated RTKs and non-RTKs whereas overexpression of the RTKs, 
often several in same tumors (including IGF1R, MET, SRC, EPHA2, KIT, ERBB3, EGRF),  
is a relatively common feature  (28)(TCGA database).   
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Two additional and closely related concepts are the phenotypic plasticity and stemness 
observed in melanoma cells. Reasons behind the phenotypic plasticity are largely unknown, 
although involvement of the melanosomal, lineage-specific transcription factor, MITF, has 
been suggested. In this model, low expression of the melanotic lineage related transcription 
factor MITF is associated with invasive and stem cell markers and ZEB2 whereas high MITF 
expression is associated with differentiation markers, high proliferative capacity and high 
ZEB1 expression (68).  
If phenotypic plasticity does take place reversing the malignant cell phenotype depending by 
extracellular stimuli, the targeting of tumor cells may become much more difficult. For 
traditional chemotherapy with DTIC, therapy resistance has been shown to largely depend on 
loss of p16
INK4A
 and alterations in p53 pathway (27)). If phenotypic plasticity is associated 
with genetic aberrations being replaced with reversible transcriptome-level alterations, then 
future therapies need to address the therapy-induced phenotypic variation. The transition 
from general cytotoxic therapies to targeted therapies has led to a change in therapy-
associated resistance: from intrinsic resistance to acquired resistance. Whether the recent 
advances in immunotherapy can help to avoid the acquired therapy resistance is to be seen.  
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2 AIMS OF THE THESIS 
 
The research presented in the thesis aims at understanding the mechanisms behind the 
aggressive nature of melanoma, here cutaneous and uveal melanoma. The ultimate purpose of 
the studies is to find prognostic markers, therapy efficacy markers and combination 
treatments that allow a more efficient, personalized cancer therapy to be used, the basis of 
which, I believe, is the genetic alterations and epigenetic modifications that are found in the 
tumors.  
 
The specific aims for the presented papers are:  
 
Paper I: to account for all known genetic and epigenetic causes of p16
INK4A
   tumor 
suppressor protein inactivation within a group of CMM tumors and to relate these with 
p16
INK4A
 protein expression. Secondarily, relate the genetic and epigenetic alterations in 
p16
INK4A
 to pathological parameters and oncogenic mutational status. 
 
Paper II: to screen for germ-line aberrations within a family with multiple cases of UM and a 
low-age of onset proband. The primary aim was to study the hereditary causes of UM, but 
also appearance of cutaneous melanomas within the family was investigated. The study was 
aimed at germ-line aberrations that segregate with UM and are present in the proband tumor.   
 
Paper III: to re-evaluate the previously published lack of association between MGMT 
inactivation and efficacy therapy with alkylating agents. Comparison between single agent 
therapy with dacarbacine (DTIC) or temozolomide (TMZ) and combination therapy 
including DTIC/TMZ in relation to MGMT promoter methylation, MGMT mRNA 
expression, therapy related toxicity and therapy outcome were studied.  
 
Paper IV: to investigate an in vitro observation regarding administration sequence 
dependency for the outcome for co-administration of mutant BRAF inhibitor and 
temozolomide. The roles of DNA damage response in relation to therapy efficacy and 
MGMT induction by mutant BRAFi were specifically focused on.   
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3 RESULTS AND DISCUSSION  
 
3.1  Results and Discussion, Paper I  
Results. Screening of transcriptional silencing of p16
INK4A
 via promoter methylation in 
CDKN2A and presence of mutations in p16
INK4A
 coding sequence revealed presence of 
silencing in 25% of tumors analyzed (15 tumors positive for methylation out of 59 eligible for 
analysis). Table 1 presents the collective results of the study with p16
INK4A
 deletion data 
derived from a previous publication (69). 
Twenty-one of the 77 analyzed metastases had bi-allelic deletions, in practice excluding them 
from mutational and methylation analyses (3 randomly chosen bi-allelic tumors were tested 
in the analyses to ascertain this). Unexpectedly, p16
INK4A
 protein expression was found to be 
absent in all of the 15 tumors confirmed to be positive for promoter methylation. Presence of 
p16
INK4A
 coding sequence alterations were confirmed in 9 out of 56 tumors successfully 
analyzed (16 % of total), with 4 tumors exhibiting typical UV exposure associated variants.  
Within NRAS mutated tumors only 9 % (n=2) were found to carry a p16
INK4A
 mutation 
despite that NRAS mutated tumors made up 41 % of all tumors eligible for analysis (Table 1). 
On the other hand, transcriptional silencing was significantly more common in NRAS mutant 
metastases compared to non-NRAS mutant metastases (p=0.0004, Table 2).  
Overall p16
INK4A
 nuclear and cytoplasmic protein expression was found to be lost in 55 
tumors (82%, Nanalyzed= 67).  In 26 out of total 56 tumors (46%) no gene deletion nor 
mutation neither transcriptional silencing could explain the lack of nuclear p16
INK4A
 protein 
expression, leaving of the observed loss of nuclear p16
INK4A
 protein expression loss 
unexplained by the mechanisms accounted for in the study.  
Fourteen of the studied metastases were accompanied by analysis of p16
INK4A
 protein 
expression in the corresponding primary tumor (Table 1). Six primary-metastasis pairs 
exhibited loss of p16
INK4A
 in the metastatic process, six pairs had identical status and two had 
reversed status with negative primary tumor and positive paired metastases.  
Discussion. The high proportion of tumors with negative p16
INK4A
 nuclear staining suggests 
that, in CMM, a large part of loss of p16
INK4A
 expression remains to be explained by 
additional mechanisms. This paper contributes to the basic understanding of p16
INK4A
 
inactivation in CMM and points out the knowledge gap regarding alternative mechanisms by 
which p16
INK4A
 protein expression can be lost.  
There are other suggestions to add to mechanisms leading to loss of p16
INK4A
 expression: ID1 
protein may function as a transcriptional repressor of CDKN2A (70). This has, however, later 
been disputed (39). In addition, high expression of enhancer of zeste homolog 2 (EZH2) 
protein, a member of polycomb protein group, has been shown to be associated with low 
p16
INK4A
 protein expression (46). In addition, transcriptional suppression by β-catenin protein 
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has been shown to be able to transcriptionally suppress p16
INK4A
 gene expression (71). 
Finally, and relatively recently, a transcriptional co-repressor, CtBP1, has been suggested to 
transcriptionally inactivate p16
INK4A
 (72). Several of these inactivating mechanisms have, 
however, not been demonstrated to be differentially expressed in melanoma tumors compared 
to normal melanocytes or normal skin.  
The antibody clone JC8 for detection of p16
INK4A
 used in Paper I has been evaluated and 
found to give cytoplasmic and nuclear staining for p16
INK4A
 protein with staining intensity 
being affected by siRNA silencing of p16
INK4A
 gene and Western blot giving a band of 
correct molecular weight (73). This is, however, not evidence for proper identification of 
p16
INK4A
 as a stringent evaluation would require knock-out and knock-in tissue for p16
INK4A
 
gene for the human protein.  
This paper has until the end of February 2015 been cited 12 times, but no citing 
publications present data to verify or to question the published significant association 
between transcriptional silencing and presence of a NRAS mutation. One publication 
commented on the lack of mRNA expression data in studies in general, including our study. 
This is simply due to that we were not confident about being able to measure mRNA 
expression for p16
INK4A
 reliably using the archival materials available. Developments in the 
field of RNA extraction from FFPE material have profoundly diminished this uncertainty. 
  
3.2 Results and Discussion, Paper II 
Results. The clinical manifestations of the proband UM are displayed in Figure 1. A large, 
highly vascular, intra-uveal melanoma of posterior origin was removed by enucleation. The 
tumor was positive for HMB-45 suggestive of presence of melanosomes of low 
differentiation grade and appeared to have a mixture of epithelioid and spindle-shaped cells. 
The metastatic tumor spread was evident in a CT scan of abdomen and scintigrafi of the 
skeleton showing numerous hepatic and skeletal metastases.  
Next-generation exome sequencing was performed using peripheral blood derived DNA 
from the proband, her sister and both parents (of which father was the obligate carrier). 
After mapping, and filtering of the variants likely to be artefactual, the remaining sequence 
variants were filtered to remove common SNP and variants present in the healthy non-
carrier (mother). The remaining variants are listed in Supplementary Table 2. As a frame-
shift, truncating insertion in the BAP1 gene was observed in the proband DNA and the 
BAP1 germ-line alterations had been linked to UM risk, DNA extracted from the proband-
derived tumor was examined using Sanger sequencing. The preservation of the observed 
frame-shift insertion chr3:52,443,617 c.75insC in the tumor DNA was verified and a 
microsatellite-based LOH analysis was performed to confirm corresponding loss of the 
wild-type BAP1 locus allele at 3p21. This frame-shift insertion results in a premature 
termination of the BAP1 protein in amino acid 43.  
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After analysis of DNA from additional family members by Sanger sequencing, the 
observed frame-shift insertion was found to segregate with UM within the family. In Figure 
2, the family pedigree with the observed BAP1 mutational status and cancer diagnoses are 
given together with a schematic picture of BAP1 with the insertion in exon 4 and 
representative fragment analyses results for the proband tumor microsatellite analysis (two 
lower panels) showing nearly complete loss of the D3S1578 157 bp repeat fragment and the 
D3S3026 211 bp repeat fragment in tumor DNA compared to blood DNA.  The inheritance 
for the microsatellite fragments is given by comparisons of the microsatellite analysis for 
the parents blood derived (upper panels) with the proband’s corresponding blood DNA 
pattern (left lower panel). In Figure 2D electropherograms for Sanger sequencing for 
mutation positive and mutation negative BAP1 screening analyses are presented for the two 
out of three brothers in first generation (I-1 and I-2), subject I-1 being analyzed for an 
archival UM tumor and subject I-2 for an archival prostate cancer tumor, probably showing 
a hemizygous BAP1 c.75insC in the former (poor DNA quality) and a heterozygous BAP1 
c.75insC in the latter. A confirmation of the next generation analysis of proband’s parents 
in shown, father displaying a heterozygous germ-line BAP1 c.75insC, mother wt sequence 
(panels II-1 and II-2). The two bottom panels show the Sanger sequencing results for the 
proband blood DNA (heterozygous c.75insC) and UM tumor (hemizygous BAP1 c.75insC). 
Note that the hemizygous BAP1 c.75insC was in both cases associated with UM tumors (I-1 
and III-1) whereas the LOH for BAP1 locus was absent in the prostate cancer tumor (I-2) 
and that the proband’s father carried a germ-line BAP1 c.75insC, but had no cancer 
diagnosis.    
Discussion. This publication was early in showing that BAP1 mutations occur as hereditary 
mutations in UM and that carriage of these mutations is associated with increased risk for 
CMM development. Both of these aspects have been since shown in a number of publications 
(summarized in (74), Table 2). It should be pointed out that this publication reflects the 
urgency felt by the involved researchers: the clinical condition of the young proband was 
rapidly deteriorating and her biological relatives could have high risk for developing similar 
malignancies.  All this together with the apparent association between the truncating BAP1 
frame-shift insertion c.75insC led to a narrow focus on this aberration within the paper.  
In hindsight, the other findings from the study (Supplementary Table 2) should have been 
more emphasized as the extended analyses for the family showed the penetrance of the germ-
line BAP1 mutation for UM and CMM to be limited to ~50% (4 family members UM or 
CMM out of 8 BAP1 c.75insC carriers) when age was not regarded. This suggests that for 
the strongly affected family members, BAP1 c.75insC may not have been the only 
susceptibility gene aberration emphasizing the usefulness of full genome sequencing data.  
There are seven external citations for this publication, two of which are review articles. This 
publication is not challenged or commented in any of the citing articles, but general 
comments concerning positive association between UM and CMM susceptibility and carriage 
of truncating BAP1 mutations are done. 
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3.3  Results and Discussion, Paper III 
Results. This paper presents a retrospective study on two CMM patient cohorts for therapy 
outcome comparison between patients with or without methylated promoter for MGMT. This 
spontaneous methylation is, similar to methylation of p16
INK4A
 promoter in Paper I, 
transcriptionally inactivating and leads to low or absent expression of the DNA repair protein 
MGMT. MGMT counteracts the effect of alkylating chemotherapy by removing the methyl 
groups from O6-methylguanine, thereby eliminating the most cytotoxic DNA lesions formed 
by dacarbacine (DTIC) or temozolomide (TMZ). The cohorts consisted of DTIC or TMZ 
single agent therapy patients (n=74, cohort S, mainly Swedish patients) and combination 
therapy patients (n=79, cohort C, mainly Belgian patients). The patients cohorts are described 
in Table 1 showing significant differences between the cohorts regarding median age at the 
start of therapy (higher in S cohort) and proportion of patients with normal or elevated level 
of pre-therapy serum lactate dehydrogenase (LDH) in blood (cohort S having higher 
proportion patients with elevated level).  
In Figure 1, images from the analyses of MGMT promoter methylation are shown, panel A 
and B including results of same four FFPE samples, using methylation-specific PCR and 
HRMA, respectively. Panel C shows a comparison of the pyrogram for the negative and 
positive methylation control DNAs derived from two melanoma cell lines. Table 2 shows a 
comparison of patients found to carry MGMT methylation positive (n=28) or negative 
(n=102) tumors. This stratification showed significant differences between the patient groups 
regarding follow-up, progression-free survival (PFS) and overall survival (OS) in a univariate 
analysis. Importantly, the pre-therapy serum LDH did not differ between these groups 
indicating no difference in tumor burden prior to therapy.  When response to therapy within 
the cohorts was compared to the MGMT methylation status (Table 2) a significant 
overrepresentation of therapy responders among patients found to carry methylated tumors 
was observed in cohort S, whereas corresponding association was not found in cohort C. 
Response here was defined as either complete or partial response, whereas stable disease was 
or progression was defined as no response. A logistic survival analyses on the pooled cohorts 
(Figure 2) further displayed a significant benefit for having positivity for MGMT methylation 
for longer PFS. To investigate whether the effect of MGMT methylation was an independent 
variable associated with PFS length, a multivariate Cox regression analysis was performed 
including dichotomized variables for gender, age at therapy start, tumor stage, pre-therapy 
serum LDH level and MGMT methylation, controlling for cohort association. Gender, pre-
therapy serum LDH and MGMT methylation were found to be independent variables for PFS 
length in these patients.  
Discussion. The significant differences between the cohorts regarding age at therapy start and 
pre-therapy serum LDH levels were likely to be influenced by the site, the cohorts being 
dominated by patients from one site each (Karolinska University Hospital, Stockholm and 
Leuven University Hospital, Belgium). These differences reflect the younger diagnosis age 
among the Belgian patients, a selection bias could possibly have induced this difference as 
combination therapy is preferentially given to younger patients due to more adverse effects 
compared to single agent therapy. The significant difference in pre-therapy LDH is 
influenced by the respective site cut-off for elevated LDH levels, but that cut-off is defined by 
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the site-specific distribution and range for the absolute LDH levels. Possibly, the cut-off 
being changed during the collection period at Karolinska University Hospital as a result of a 
general decrease in LDH values at diagnosis by time influenced the distribution of patients 
for this cohort.  None of these factors were likely to have a profound effect on the MGMT 
methylation as being an independent variable defining the PFS length, as the multivariate 
model did control for both of these variables. On the other hand, gender was also found to be 
an additional independent variable associated with PFS length. This association is not 
obvious, as no significant skewness in the gender distribution for patients found to have 
MGMT methylated and unmethylated tumors was observed (Table 2) in the univariate 
analysis. Importantly though, the patient material from Leuven University Hospital 
(constituting a great majority of cohort C patients) was found to have a gender difference 
regarding the tumor stages and, consequently, males showed a borderline significance for 
having lower tumor stage and median LDH value. This gender difference did, however, not 
apply for the cohort S patients, why the initial advantage of males in cohort C patients must 
be assumed to have caused the male gender to be independently associated with longer PFS. 
Corresponding multivariate analysis for OS did also show the same independent variables to 
be significant for OS length as for PFS, with gender being an exception (Supplementary 
Table 2S). This difference was studied in univariate analyses showing that despite males in 
cohort C had lower tumor stage and pre-therapy LDH levels, comparison of OS length for 
males and females did not result in a significant difference. This can probably only be 
interpreted as the beneficial effect by the female gender regarding survival as the effect by 
MGMT methylation positivity in this cohort did not show significant association to OS length 
either in a Kaplan-Meier survival analysis or in a univariate comparison of genders. 
In relation to this, the OS length was significantly associated with MGMT methylation 
positivity in cohort S, but not in cohort C why the multivariate analysis for OS did show 
significant interaction between cohort and MGM T methylation (Supplementary Table 2S). 
The inclusion of mRNA measurements for tumors with MGMT methylation status (n=42 and 
n=44 for cohort S and C, respectively) did show a highly significant correlation to 
methylation (chapter ¨MGMT promoter methylation in relation to MGMT mRNA 
expression¨) strengthening the validity of the methylation analyses. As presented in the 
Supplementary section, the association between the MGMT mRNA expression and MGMT 
methylation was strong in both cohorts (Supplementary Figure 5S) while the associations 
between HRMA Tm values and response status on one hand, and MGMT mRNA expression 
and response status on the other hand, were stronger in cohort S.   This is likely to reflect the 
enrichment of cohort S patients with complete responders and the clearer association between 
therapy outcome with alkylating agents alone compared to outcome with co-administration of 
an alkylating drug with an additional agent.  
 
 
3.4  Results and Discussion, Paper IV 
Results.  The therapeutic efficacy after co-administration of TMZ and mutant BRAF inhibitor 
PLX4720 was found to be dependent on the administration order. This administration order 
effect was only found to be associated with increased therapy efficacy when TMZ was 
administered before PLX4720 both in the A375 parental cell line and the A375-PLX4720R 
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resistant subline (Figure 1 panels A-C). No corresponding effect by administration order was, 
however, observed in the SK-Mel-24 cell line that harbors a transcriptionally silenced MGMT 
(panels 1D and 1E). To investigate the possible role of MGMT in the combination therapy, 
both parental and PLX4720 resistant A375 cells were treated with PLX4720 and MEK 
inhibitor trametinib to show induction of MGMT mRNA by both drugs (Figure 2A). The 
constitutive MGMT expression of A375-PLX4720R was found to be lower (approximately 
50% of corresponding level for parental A375) (Figure 2B). In addition, treatment of A375-
PLX4720R with the clinically approved, specific inhibitor lomeguatrib, significantly reduced 
the MGMT protein level in administration with PLX4720 before TMZ (induction of MGMT 
was abolished) (Figure 2C). Utilizing Annexin V-FLUOS and PI staining the cytotoxicity of 
the single agent and combination therapy administrations were investigated. Administration 
of TMZ for 72h with addition of PLX4720 at 48 h showed similar early apoptotic/necrotic 
and apoptotic response in both parental A375 and A375-PLX4720R with only PLX4720 or 
TMZ exposure associated with approximately doubling of both types of cell death. 
Combination of these drugs enhanced cell death further, and addition of MGMTi lomeguatrib 
roughly doubled cell death when added to PLX4720 and TMZ (Figures 3A and 3B). To 
investigate the mechanistic background of these effects, immunoblotting was performed for 
cell lysates from both parental and resistant cells. Lomeguatrib (patrin) was found to 
efficiently down-regulate MGMT in both cell lines, PLX4720 was found to upregulate 
MGMT expression and this up-regulation was abolished by lomeguatrib (Figures 4A and 
4B). Tumor suppressor protein p53 stabilization was found to be associated with TMZ 
administration, but TMZ alone did not induce γH2AX formation at 72h.  Instead, 
combination of PLX4720 and TMZ induced γH2AX formation profoundly but the same was 
true for combination of MGMTi and PLX4720 for both cell lines (at 72h). The combination 
of MGMTi with PLX4720 and TMZ showed the strongest induction of γH2AX formation in 
both cell lines. The time-line for induction of γH2AX in parental A375 (Figure 5) did show 
separate peaks for induction of γH2AX form by PLX4720 (peaking at 48h) and TMZ 
(peaking starting at 96h) as expected by the results in Figure 4A and 4B. 
Discussion. The studied effect of the administration order for combination TMZ and BRAFi 
PLX4720 is suggests that when combinations of drugs are employed, the administration order 
of the drugs may play an important role for therapeutic efficacy. These effects can only be 
studied pre-clinically given the numerous different drugs for therapy and the possible 
administration combinations. The data presented in Paper IV advocates a role for MGMT in 
the combination therapy with TMZ and BRAFi. The enhancing cytotoxic effect by inhibiting 
MGMT in the combination therapy setting is not surprising given that MGMTi can enhance 
the effect of TMZ in the combination. On the other side, the induction of γH2AX by addition 
of MGMTi to PLX4720 compared to PLX4720 or MGMTi (lomeguatrib, Patrin) alone is 
puzzling (Figure 4A and 4B).  In addition to this effect being early compared to the enhanced 
induction of γH2AX by combining TMZ and MGMTi, the mere suggestion that BRAFi 
PLX4720 administration is associated with dsDNA break marker despite PLX4720 not being 
an alkylator is unexpected. Also, γH2AX expression was enhanced by inhibition of MGMT 
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together with BRAFi compared to BRAFi alone despite that MGMT has only been associated 
with efficacy of alkylating agents. These effects are not explained by the data presented in 
this manuscript, but offer surely a basis for further experiments.  
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4 THESIS CONCLUSIONS 
 
Paper I:   A large part of loss of protein expression for p16
INK4A
 in cutaneous melanoma 
metastases cannot be associated with conventionally studied inactivating 
mechanisms like gene deletion, gene mutation or p16
INK4A
 mRNA 
transcriptional inactivation by promoter methylation. A significant larger 
proportion of NRAS mutated metastatic CMM tumors appear to have 
simultaneous transcriptional inactivation compared to non-NRAS mutated 
tumors. 
Paper II:  Unlike CMM, deletion or mutation in p16
INK4A
 gene disruption appear to be 
rare in UM. Instead, BAP1 tumor suppressor gene is found to be mutated in the 
germ-line of hereditary UM families and loss of BAP1 wt allele in locus 3p21 
is associated with UM development. The penetrance of the truncating BAP1 
germ-line mutation was, however, found to be limited, but an association to an 
increased risk for CMM and formation of dysplastic nevi was observed. 
Paper III: Opposite to earlier publication (75) presenting results for MGMT inactivation in 
CMM tumors for not being beneficial for therapy efficacy when using 
alkylating agents DTIC or TMZ, our published results suggest positivity for 
MGMT methylation being associated with longer PFS. The effect of MGMT 
silencing, confirmed by MGMT mRNA down-regulation, was more evident in 
DTIC/TMZ single agent therapy patients as would be expected by combination 
therapy resulting in responses unrelated to DTIC or TMZ.  
Paper IV: The observed effect of administration order on efficacy of combination therapy 
with TMZ and mutant BRAFi PLX4720 with enhanced efficacy with TMZ 
administered first was found to be related to PLX4720 induction of MGMT. As 
a consequence, enhanced MGMT in PLX4720 pre-incubation lowered the 
efficacy of following TMZ administration. Early time-point effects by 
PLX4720 on dsDNA strand break marker γH2AX formation were observed 
with enhanced induction of γH2AX by combining PLX4720 with MGMTi 
lomeguatrib despite that MGMT is not known to be associated with targeted 
therapy. 
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